Your browser doesn't support javascript.
loading
SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population.
Moreno-Cabrera, José M; Feliubadaló, Lidia; Pineda, Marta; Prada-Dacasa, Patricia; Ramos-Muntada, Mireia; Del Valle, Jesús; Brunet, Joan; Gel, Bernat; Currás-Freixes, María; Calsina, Bruna; Salazar-Hidalgo, Milton E; Rodríguez-Balada, Marta; Roig, Bàrbara; Fernández-Castillejo, Sara; Durán Domínguez, Mercedes; Arranz Ledo, Mónica; Infante Sanz, Mar; Castillejo, Adela; Dámaso, Estela; Soto, José L; de Miguel, Montserrat; Hidalgo Calero, Beatriz; Sánchez-Zapardiel, José M; Ramon Y Cajal, Teresa; Lasa, Adriana; Gisbert-Beamud, Alexandra; López-Novo, Anael; Ruiz-Ponte, Clara; Potrony, Miriam; Álvarez-Mora, María I; Osorio, Ana; Lorda-Sánchez, Isabel; Robledo, Mercedes; Cascón, Alberto; Ruiz, Anna; Spataro, Nino; Hernan, Imma; Borràs, Emma; Moles-Fernández, Alejandro; Earl, Julie; Cadiñanos, Juan; Sánchez-Heras, Ana B; Bigas, Anna; Capellá, Gabriel; Lázaro, Conxi.
Afiliação
  • Moreno-Cabrera JM; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Feliubadaló L; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Pineda M; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
  • Prada-Dacasa P; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Ramos-Muntada M; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Brunet J; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Gel B; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Currás-Freixes M; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Calsina B; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Salazar-Hidalgo ME; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Rodríguez-Balada M; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Roig B; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Fernández-Castillejo S; Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Durán Domínguez M; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
  • Arranz Ledo M; Hereditary Cancer Group, Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Ctra de Can Ruti, Camí de les Escoles, s/n, Badalona 08916, Spain.
  • Infante Sanz M; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain.
  • Castillejo A; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain.
  • Dámaso E; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain.
  • Soto JL; Institut d'Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus (HUSJR), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Dr. Josep Laporte, 2, Reus 43204, Spain.
  • de Miguel M; Institut d'Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus (HUSJR), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Dr. Josep Laporte, 2, Reus 43204, Spain.
  • Hidalgo Calero B; Institut d'Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus (HUSJR), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Dr. Josep Laporte, 2, Reus 43204, Spain.
  • Sánchez-Zapardiel JM; Cancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid-Spanish National Research Council (IBGM, UVa- CSIC), Sanz y Fores, 3, Valladolid 47003, Spain.
  • Ramon Y Cajal T; Cancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid-Spanish National Research Council (IBGM, UVa- CSIC), Sanz y Fores, 3, Valladolid 47003, Spain.
  • Lasa A; Cancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid-Spanish National Research Council (IBGM, UVa- CSIC), Sanz y Fores, 3, Valladolid 47003, Spain.
  • Gisbert-Beamud A; Unidad de Genética Molecular, Hospital General Universitario de Elche. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Av. de Catalunya, 21, Elche 03203, Spain.
  • López-Novo A; Unidad de Genética Molecular, Hospital General Universitario de Elche. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Av. de Catalunya, 21, Elche 03203, Spain.
  • Ruiz-Ponte C; Unidad de Genética Molecular, Hospital General Universitario de Elche. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Av. de Catalunya, 21, Elche 03203, Spain.
  • Potrony M; Laboratorio de cáncer hereditario, Servicio de Bioquímica clínica-Análisis clínicos, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Madrid 28041, Spain.
  • Álvarez-Mora MI; Laboratorio de cáncer hereditario, Servicio de Bioquímica clínica-Análisis clínicos, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Madrid 28041, Spain.
  • Osorio A; Laboratorio de cáncer hereditario, Servicio de Bioquímica clínica-Análisis clínicos, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Madrid 28041, Spain.
  • Lorda-Sánchez I; Familial Cancer Clinic, Medical Oncology, Hospital de la Santa Creu i Sant Pau, Sant Quintí, 89, Barcelona 08041, Spain.
  • Robledo M; Genetics Department, Hospital de la Santa Creu i Sant Pau, Sant Quintí, 89, Barcelona 08041, Spain.
  • Cascón A; Biomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
  • Ruiz A; Institut de Recerca Sant Pau (IR Sant Pau), Sant Quintí, 77, Barcelona 08041, Spain.
  • Spataro N; Fundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, Grupo de Medicina Xenómica-USC, Av. Barcelona, s/n, Santiago de Compostela 15706, Spain.
  • Hernan I; Biomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
  • Borràs E; Fundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, Grupo de Medicina Xenómica-USC, Av. Barcelona, s/n, Santiago de Compostela 15706, Spain.
  • Moles-Fernández A; Biomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
  • Earl J; Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Rosselló, 149, Barcelona 08036, Spain.
  • Cadiñanos J; Biomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
  • Sánchez-Heras AB; Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Rosselló, 149, Barcelona 08036, Spain.
  • Bigas A; Biomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
  • Capellá G; Departamento de Genética y Genómica, Hospital Universitario Fundación Jiménez Diaz (IIS-FJD), Av. de los Reyes Católicos, 2, Madrid 28040, Spain.
  • Lázaro C; Biomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
Database (Oxford) ; 20242024 Jul 04.
Article em En | MEDLINE | ID: mdl-38965703
ABSTRACT
Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management. Database URL https//spadahc.ciberisciii.es/.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bases de Dados Genéticas Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Database (Oxford) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bases de Dados Genéticas Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Database (Oxford) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha